Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
Obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the new medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback